Additional file 2: Table S2. of Elevated expression of HSP90 and the antitumor effect of an HSP90 inhibitor via inactivation of the Akt/mTOR pathway in undifferentiated pleomorphic sarcoma

Immunohistochemical Results and Their Statistical Analysis. EFS, event-free survival; LI, labeling index; OS, overall survival; pAkt, phosphorylated protein kinase B; p-ERK1/2, phosphorylated-extracellular signal-regulated kinase1/2; p-4EBP, phosphorylated eukaryotic translation initiation factor 4E-binding protein; p-MEK1/2, phosphorylated mitogen-activated protein kinase1/2; p-mTOR, phosphorylated mammalian target of rapamycin; p-S6RP, phosphorylated S6 ribosomal protein; PTEN, phosphatase and tensin homologue. The Fisher exact test or the log-rank test was used if not indicated otherwise. a: p < 0.05. b: Comparison of no necrosis and presence of necrosis. c: Comparison of 0–9/10 HPF and 10/10 HPF. d: Comparison of stage II and stage III or IV. (XLSX 12 kb)免疫组织化学结果及其统计学分析。无事件生存期（event-free survival, EFS）；标记指数（labeling index, LI）；总生存期（overall survival, OS）；磷酸化蛋白激酶B（phosphorylated protein kinase B, pAkt）；磷酸化细胞外调节蛋白激酶1/2（phosphorylated-extracellular signal-regulated kinase1/2, p-ERK1/2）；磷酸化真核翻译起始因子4E结合蛋白（phosphorylated eukaryotic translation initiation factor 4E-binding protein, p-4EBP）；磷酸化丝裂原活化蛋白激酶1/2（phosphorylated mitogen-activated protein kinase1/2, p-MEK1/2）；磷酸化雷帕霉素靶蛋白（phosphorylated mammalian target of rapamycin, p-mTOR）；磷酸化S6核糖体蛋白（phosphorylated S6 ribosomal protein, p-S6RP）；张力蛋白同源磷酸酶（phosphatase and tensin homologue, PTEN）。若无特殊说明，采用Fisher确切概率法或对数秩检验进行统计分析。a：p < 0.05。b：无坏死组与存在坏死组的比较。c：0~9/10高倍视野组与10/10高倍视野组的比较。d：Ⅱ期与Ⅲ期或Ⅳ期的比较。（XLSX 12 KB）